We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+13.92%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$104M
Cap. Flow
-$16.3M
Cap. Flow %
-0.99%
Top 10 Hldgs %
51.14%
Holding
80
New
16
Increased
18
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.2M
2
ABBV icon
AbbVie
ABBV
+$49.4M
3
BSX icon
Boston Scientific
BSX
+$43.6M
4
UTHR icon
United Therapeutics
UTHR
+$35.4M
5
LLY icon
Eli Lilly
LLY
+$34.4M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$111M
2
MDT icon
Medtronic
MDT
+$50.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.6M
4
BPMC
Blueprint Medicines
BPMC
+$23.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
51
CALL
Cogent Biosciences
COGT
$6.79B
$4.74M 0.29%
+660,000
New +$3.66M
APGE icon
52
Apogee Therapeutics
APGE
$10.2B
$3.31M 0.2%
+76,180
New +$2.9M
NXTC icon
53
NextCure
NXTC
$17.3M
$1.23M 0.08%
222,655
– –
ESTA icon
54
Establishment Labs
ESTA
$2.72B
$1.2M 0.07%
28,120
-555
-2% -$19.4K
JBIO
55
Jade Biosciences
JBIO
$1.22B
$1.07M 0.07%
107,391
– –
MTSR
56
DELISTED
Metsera Inc
MTSR
$1.03M 0.06%
36,191
-609
-2% -$15.1K
SRRK icon
57
Scholar Rock
SRRK
$5.71B
$937K 0.06%
26,440
-89,677
-77% -$2.81M
BOLT icon
58
Bolt Biotherapeutics
BOLT
$7.36M
$795K 0.05%
137,721
-1
-0% -$7
WVE icon
59
Wave Life Sciences
WVE
$1.12B
$766K 0.05%
+117,903
New +$779K
GPCR icon
60
Structure Therapeutics
GPCR
$3.49B
$712K 0.04%
34,353
-599
-2% -$13.2K
PRAX icon
61
Praxis Precision Medicines
PRAX
$9.07B
$661K 0.04%
15,717
-141,923
-90% -$5.4M
IMA
62
ImageneBio Inc
IMA
$63.1M
$513K 0.03%
31,885
– –
IRON icon
63
Disc Medicine
IRON
$2.83B
$387K 0.02%
7,312
-173
-2% -$8.13K
ACAD icon
64
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
– –
-500,000
Closed -$8.3M
ALNY icon
65
Alnylam Pharmaceuticals
ALNY
$36.3B
– –
-176,181
Closed -$47.6M
BMY icon
66
Bristol-Myers Squibb
BMY
$127B
– –
-371,497
Closed -$22.7M
BPMC
67
DELISTED
Blueprint Medicines
BPMC
– –
-261,039
Closed -$23.1M
DHR icon
68
Danaher
DHR
$135B
– –
-58,606
Closed -$12M
ELVN icon
69
Enliven Therapeutics
ELVN
$3.78B
– –
-33,547
Closed -$660K
ERAS icon
70
Erasca
ERAS
$6.63B
– –
-1,877,085
Closed -$2.57M
EWTX icon
71
PUT
Edgewise Therapeutics
EWTX
$4.39B
– –
-320,400
Closed -$7.05M
INCY icon
72
Incyte
INCY
$23.5B
– –
-357,800
Closed -$21.7M
KURA icon
73
Kura Oncology
KURA
$922M
– –
-791,667
Closed -$5.23M
MDT icon
74
Medtronic
MDT
$107B
– –
-562,992
Closed -$50.6M
PEN icon
75
Penumbra
PEN
$12.5B
– –
-42,936
Closed -$11.5M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Sofinnova Investments held 80 positions worth $1.64B, up 6.8% from $1.53B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments's Q2 2025 filing shows 16 new, 18 increased, 19 reduced and 17 closed positions. Its largest new stake was AbbVie: 265,850 shares worth $49.3M. The largest sale was Stryker, an estimated $111M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

  • Sofinnova Investments's largest Q2 2025 buy was AbbVie: 265,850 shares worth $49.3M.
  • Sofinnova Investments added most to Gilead Sciences in Q2 2025, an estimated $67.2M increase.
  • Sofinnova Investments's biggest Q2 2025 reduction was PTC Therapeutics, cutting an estimated $9.66M.
  • Sofinnova Investments fully exited Stryker in Q2 2025, selling an estimated $111M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.64B portfolio in Q2 2025.
  • Sofinnova Investments opened 16 new positions and closed 17 in Q2 2025.
  • Sofinnova Investments's portfolio value rose 6.8% quarter-over-quarter to $1.64B.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.